|
Characteristics of the study population
|
Level
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
OR (95% CI)
|
P
|
OR (95% CI)
|
P
|
|---|
|
Age group (Years)
|
< 30
|
1
|
0.02
|
1
| |
|
30–40
|
0.15 (0.03–0.65)
|
0.16 (0.04–0.72)
|
0.03
|
|
> 40
|
0.40 (0.11–1.47)
|
0.32 (0.08–1.24)
|
0.1
|
|
Gender
|
Male
|
1
|
0.04
|
1
| |
|
Female
|
0.26 (0.895.28)
|
1.78 (0.58–5.49)
|
0.32
|
|
Body Mass Index
|
Normal
|
1
|
0.02
|
1
| |
|
Low
|
0.38 (0.04–3.35)
|
0.33 (0.11-0.99)
|
0.04
|
|
Overweight
|
0.30 (0.11-0.78)
|
0.35 (0.21–4.59)
|
0.11
|
|
Monthly income
|
< 50,000
|
1
|
0.01
|
1
| |
|
> 50,000
|
0.18 (0.04–0.86)
|
0.14 (0.030.79)
|
0.02
|
|
Alcohol intake
|
No
|
1
|
0.07
|
1
| |
|
Yes
|
0.40 (0.11-0.47)
|
0.42 (0.09–1.64)
|
0.1
|
|
Cigarette or tobacco intake
|
No
|
1
|
0.09
|
1
| |
|
Yes
|
2.26 (0.885.80)
|
1.68 (0.51–5.60)
|
0.39
|
|
CD4 Count values
|
< 200
|
1
|
0.06
|
1
| |
|
> 200
|
0.42 (0.16–1.08)
|
0.65 (0.34–2.37)
|
0.16
|
|
Name of ARV regimen
|
TDF + 3TC + EFV
|
1
|
0.01
|
1
| |
|
AZT + 3TC + EFV
|
0.25 (0.05–1.18)
|
0.18 (0.03–0.99)
|
0.22
|
|
AZT + 3TC + NVP
|
2.86 (0.90–9.04)
|
2.44 (0.58–10.26)
|
0.03
|
- 3TC: Lamivudine, AZT: Zidovudine, BMI: Body mass index, EFV: Efavirenz, NVP: Nevirapine; TDF: Tenofovir
